Principal Investigator
Olimpia Carbunar
Enrollment Status
Not Accepting
Clinical Trial ID
Institutional Protocol #
20220892
Clinical Trial Summary
Influence of NT5c1A antibodies on disease progression, clinical phenotype and blood and muscle biomarkers in sporadic Inclusion Body Myositis A prospective evaluation (INSPIRE-IBM)
Phase
Other
Funding Agency/Sponsor
Other
Disease
Neuro-Muscular Disorders
Contact Information
Study Contact
Olimpia Carbunar
Phone Number
+1 (305) 2433100
Email
oxc163@miami.edu